What You Should Know:
– OpenEvidence, a medical search and AI platform for clinicians, has acquired Amaro, an AI-native advertising company backed by Google Ventures and Greycroft. Financial details of the acquisition were not disclosed.
– Amaro was founded by Kush Khosla and Sauren Khosla and was built to help companies analyze and optimize end-to-end advertising deployment using intelligent automation. This acquisition expands OpenEvidence’s platform capabilities, particularly in building a modern, sustainable, and user-first advertising infrastructure for healthcare professionals.
A Strategic Move to Support Clinicians
OpenEvidence is used by more than 40% of physicians in the United States who log in daily to make high-stakes clinical decisions at the point of care. The platform is currently adding 90,000 clinicians per month.
By integrating Amaro’s team, product, and technology, OpenEvidence plans to enhance its platform with a user-first advertising infrastructure. This strategic move aims to support healthcare professionals with a more sustainable and modern approach to advertising.
“OpenEvidence powers over half a million clinical conversations per day to verified American clinicians–for free. We believe every patient deserves to be seen by physicians with access to the highest quality information in the world, and our free-to-physician, ad-supported model enables every single practice in the country to leverage this technology, no matter the level of resources available to them,” said Zachary Ziegler, cofounder of OpenEvidence. “The Amaro team moves fast, ships relentlessly, and shares our obsession with quality. This acquisition gives us a huge boost as we scale, and Amaro is a natural fit that accelerates our vision.”
